The “microdosing” dilemma: Balancing patient anecdotes with clinical safety amid GLP-1 compounding restrictions
Journal of the American Association of Nurse Practitioners May 26, 2026 Nicole Trainer
The recent resolution of semaglutide and tirzepatide shortages by the FDA has changed the regulatory landscape for compounded obesity medications. Despite federal pricing agreements to reduce GLP-1 costs, affordability barriers persist, driving patients toward unsupervised strategies such as microdosing and purchasing illicit research-grade peptides from online sources and unregulated providers like medical spas. This report addresses critical gaps for nurse practitioners: the drivers behind subtherapeutic microdosing, specific side effects and dosing errors, safety risks from pen manipulation and compounded vials, and legal pitfalls of compounded copies. Provider weight bias is examined as a driver of patients toward unregulated alternatives, with strategies to mitigate stigma.